TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: SUV on PSMA PET/CT in Non-Prostate Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older, able to understand and provide written informed consent~* The patient has a tumor known or suspected to have PSMA expression, as reported in the literature or by positive histopathological staining for PSMA.~* The known or suspected tumor must fall into one of the following categories: carcinoma, sarcoma, or hematologic cancer.~* ECOG performance status 0 - 3, inclusive~* Under referring physician's care~* Able to tolerate the physical/logistical requirements of a PET/CT scan including lying supine for up to 40 minutes with the arms above the head and tolerating intravenous cannulation~Exclusion Criteria:~* Patients with neoplasm known in literature to not have PSMA expression, unless patient specific tissue sampling shows PSMA staining on histopathology.~* Medically unstable patients (e.g. acute cardiac or respiratory distress or hypotensive, etc.)~* Patients who exceed the safe weight limit of the PET/CT bed (200 kg) or who cannot fit through the PET/CT bore (70 cm diameter)~* Patients with unmanageable claustrophobia~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- PSMA PET/CT (Type: EXPERIMENTAL): One (1) PSMA PET/CT scan with with either PSMA-11 or DCFPyL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~patients age 18 years or above undergoing elective total hip or knee replacement surgery~Exclusion criteria:~according to the label recommendation for Pradaxa 220 mg QD

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- patients after hip or knee replacement (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Rosiglitazone in the Treatment of Endometriosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy women ages 18 - 45 years.~* Regular menstrual cycles (24-35 days).~* Pelvic pain ≥ 3 months with cyclical component.~* Negative pregnancy test and must use nonhormonal contraception.~* Non-lactating.~* No history of liver disease.~* Consent to participate in the study.~* Endometriosis diagnosed from surgical specimen by routine hematoxylin and eosin staining and histological evaluation within the past 4 years.~Exclusion Criteria:~* Major psychiatric conditions or the abuse of alcohol or drugs which would make it difficult for the subject to complete study procedures.~* Active or prior infection with hepatitis, human immunodeficiency virus (HIV) infection, or history of high-risk activities (e.g., IV drug abuse) which would increase risk to laboratory personnel. Of note, no testing for hepatitis or HIV will be performed as part of this study and all tissues will be handled and discarded as if they were potentially infected.~* Patients with liver dysfunction (elevated liver enzymes \> 2 times the upper limit of normal).~* Presence of pre-existing malignancy, including carcinoma of the breast or uterus.~* Women with other causes of chronic pelvic pain including infectious, gastrointestinal, musculoskeletal, neurologic or psychiatric.~* Elevated WBC.~* NYHA functional class I-IV heart failure.~* Diabetics.~* Known pregnancy or positive pregnancy test.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Consolidation PET-based and Donor-based After Salvage Therapy in Patients With HL in Relapse or Refractory

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients confirmed Hodgkin's lymphoma at refractory at first line therapy, relapse early or late;~* Age \> 18 years;~* Life expectancy \> 3 months;~* Cardiac, pulmonary, renal and liver functions with normal range;~* Written informed consent.~Exclusion Criteria:~* Any psychological, familiar or geographical conditions that could potentially hinder the compliance to the protocol;~* renal failure as creatinine\> 1.2 mg/dl or creatinine clearance \<60 ml/min;~* AST/ALT or bilirubin\> 2.5 times the norm;~* HCV positivity with signs of ongoing viral replication (HCV PCR + AST\>1.5-2x normal);~* Heart disease clinically significant: eg. severe hypertension not controlled, multifocal uncontrolled cardiac arrhythmias, symptomatic ischemic heart disease or congestive heart failure class NYHA class III-IV (Annex 2), previous acute myocardial infarction;~* Ventricular ejection fraction \<45%;~* decompensated diabetes mellitus not controlled by insulin therapy; Disease with significant pulmonary function defined as FEV1 \<65% of predicted or DLCO \<50% of predicted value;~* HIV positive patients;~* Patients with uncontrolled infection;~* Neoplasia in the last 3 years except carcinoma in situ uterus, neck and basal skin cancer or prostate cancer in early stage localized exeresi treated with surgery or brachytherapy with curative intent, a good prognosis DCIS breast treated with surgery alone;~* Drug addiction or alcoholism.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Postoperative Pain Control After Hip Hemiarthroplasty: Intrathecal Morphine vs Periarticular Infiltration of Bupivacaine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* age between 18-90 years~* Co-operative, able to use PCA~* ASA classification 1-3~* no contraindication for Spinal Anesthesia~* patient acceptance for spinal anesthesia~* body weight \> 30 kg.~* BMI between 20-35~* no history of drug allergy, e.g. Local Anesthetics, Paracetamol, etc.~Exclusion Criteria:~* age \> 90 years~* previous Hemiarthroplasty (the same site)~* pathological fracture such as severe infection, bone cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- control (Type: PLACEBO_COMPARATOR): The patient will be performed spinal anesthesia alone, with postoperative PCA
- Morphine (Type: ACTIVE_COMPARATOR): The patient will received intrathecal Morphine for 0.1 mg. in Isobaric bupivacaine in spinal anesthesia and postoperative PCA
- bupivacaine (Type: ACTIVE_COMPARATOR): the patients will be received spinal anesthesia and periarticular tissue infiltration with 0.25% Bupivacaine and postoperative pain control by IV PCA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Metastatic Tumors to the Liver

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic confirmation of solid primary tumor metastatic to liver~* Age greater than or equal to 18 years old~* Zubrod performance status less than or equal to 1~* Negative pregnancy test for women of child bearing potential~* Informed consent~* Less than or equal to 3 liver metastases~* Each lesion must be less than or equal to 6 cm in maximal diameter~* No prior radiation to lesions being treated~* Patient is not a surgical candidate or refuses surgery~* Absolute neutrophil count ≥ 1800~* Platelets ≥ 100000~* Hemoglobin ≥8.0~* Systemic therapy (chemotherapy) completed at least 2 weeks prior to SBRT~* At time of radiation treatment planning, at least 700 cc of normal liver must receive less than 15 Gy~Exclusion Criteria:~* Contraindications to radiation~* Pregnant or lactating females who chose to breast feed~* Patients must have recovered from toxicity of prior therapy~* Any co morbid condition that' in the view of the attending physician' renders the patient at high risk from treatment complications~* Patients currently receiving anticoagulation with coumadin or IV heparin~* Liver cirrhosis~* Clinical ascites~* Bilirubin \> 3, Albumin \< 2.5, liver enzymes 3 times above normal, Creatinine \> 1.8

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tomotherapy (Type: EXPERIMENTAL): Intervention: Stereotactic Body Radiation Therapy using Tomotherapy. Tomotherapy treatment: A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days. Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours. Dose will be prescribed to the isodose line which covers at least 90% of the PTV.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 18 years old~2. Heart Failure Reduced ejection fraction (HFrEF) of 40 or less~3. Estimated glomerular filtration rate (eGFR) \> 30milliliters(ml)/minute(min)/1.73 meter(m)2~4. Admitted to CCU by advanced heart failure service for decompensated heart failure requiring continuous hemodynamic monitoring with a pulmonary artery catheter~Exclusion Criteria:~1. Diagnosis of type 1 diabetes mellitus~2. eGFR \< 30ml/min/1.73m2~3. age \< 18 years old~4. Jehovah's witnesses~5. Diagnosis of group 1 pulmonary arterial hypertension~6. Insulin requirement above standard low dose sliding scale~7. Patients with a history of diabetic ketoacidosis (DKA)~8. Allergies to SGLT2i medications~9. History of intolerance to SGLT2i medications~10. Patients listed for cardiac transplantation or on mechanical support~11. Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SGLT2i (Type: ACTIVE_COMPARATOR): Participants will be treated with a SGLT2i during their ICU stay. The SGLT2i and heart failure care will be managed according to routine care, and data will be collected from the participant's medical record.
- No SGLT2i (Type: ACTIVE_COMPARATOR): Participants will not be treated with a SGLT2i during their ICU stay. Heart failure care will be managed according to routine care, and data will be collected from the participant's medical record.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Ptosis to Muscular Dystrophy Oculopharyngeal by Myoblast Autologous Graft

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ( with suitable contraception) over 18 years of age 75~* OPMD confirmed by genetic diagnosis ( gene mutation PABPN1 by triplet expansion GCG)~* OPMD with ptosis~* Obtaining informed consent signed~Exclusion Criteria:~* Evolutionary contagious infectious pathology~* Inflammatory diseases~* Any other neuromuscular disease~* Malignant tumor pathology of history~* Renal impairment ( creatinine clearance \< 60ml / min)~* Hepatic insufficiency~* Pregnant woman confirmed by a dosing B-HCG or lactating~* Inability to perform a muscle biopsy~* Preparation of myoblasts uncommitted to step 2nd release~* Inability to follow up to 36 months~* Refusal to sign the consent form~* No Social Security

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Myoblast autologous graft (Type: EXPERIMENTAL): 30 million autologous myoblasts in 6 intramuscular injections

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Weekly Antepartum Testing in Women With BMI 30-40 and Neonatal Outcomes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women at or over 18 years of age~* Singleton pregnancy with no major fetal anomalies~* Pregnancies and gestational age will be well dated~* Obese with BMI 30-40kg/m2~Exclusion Criteria:~* Women with any complications at time of randomization that would require antenatal testing in the third trimester as per ACOG guidelines including: hypertension, systemic lupus erythematosus, chronic renal disease, antiphospholipid syndromes, hyperthyroidism poorly controlled, hemoglobinopathies, cyanotic heart disease, gestational hypertension, pre-eclampsia, gestational diabetes medication controlled, oligohydramnios, intrauterine growth restriction before randomization, isoimmunization, history of fetal demise~* Women with indication for weekly testing as per local protocol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Weekly antenatal testing (Type: OTHER): Women with BMI 30-40 between 20 and 34.6 weeks of gestation will receive weekly antenatal testing (biophysical profile) starting at 34 weeks as well as growth ultrasound every 4 weeks.
- Growth ultrasound examination every 4 weeks (Type: OTHER): Women with BMI 30-40 between 20 and 34.6 weeks of gestation will receive ultrasound examination (growth ultrasound) every 4 weeks starting at 34 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Coherex FlatStent™ EF PFO Migraine Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Major Inclusion Criteria:~Age 18-65 males and non pregnant females History of refractory migraine Documented PFO~Major Exclusion Criteria:~Known allergy to aspirin or nickel. Medication Overuse Headache Body mass index \> 40. Recent Botulinum neurotoxin type A treatment Other known structural heart disease, coronary artery disease, atrial fibrillation PFO morphology not suitable for FlatStent EF Patients who have had a stroke within the past two months Post-traumatic headache. Patients with diagnosed hypercoagulable states that require chronic treatment with warfarin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Rehabilitation and Quality of Life Assessment for Soft Tissue Sarcoma Treated With Radiotherapy and Surgery

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed soft tissue sarcoma of the extremity, or superficial trunk (abdomen or chest)~* Planning to receive radiotherapy and surgical resection~* At least 16 years of age.~* ECOG performance status ≤ 3~* Able to complete the cancer rehabilitation protocol safely, as determined by a treating physician.~* Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).~Exclusion Criteria:~* Patients deemed ineligible for curative therapy by the treating medical oncologist, radiation oncologist, or surgeon.~* Patients with deep retroperitoneal or abdominal STS~* Patients who have received prior radiotherapy and, based on the treating radiation oncologist's opinion, may not safely be treated with protocol neoadjuvant radiotherapy.~* Currently receiving any investigational agents.~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.~* Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test prior to starting radiotherapy.~* HIV-positive patients whose CD4+ T-cell count is \< 350 cells/mcL.~* Receiving concurrent chemoradiation therapy

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pre-Operative Radiotherapy: Dietary Counseling/Exercise/Psychological Counsel (Type: EXPERIMENTAL): * Patients must be treated using daily image-guided radiotherapy~* Dietary counseling at baseline~* Exercise intervention throughout cancer rehabilitation protocol~* Psychological screening with counselling services as needed - nurse will administer the NCCN distress thermometer and refer the patient to applicable psychological counselling
- Post-Operative Radiotherapy: Dietary Counseling/Exercise/Psychological Counsel (Type: EXPERIMENTAL): * Patients must be treated using daily image-guided radiotherapy~* Dietary counseling at baseline~* Exercise intervention throughout cancer rehabilitation protocol~* Psychological screening with counselling services as needed - nurse will administer the NCCN distress thermometer and refer the patient to applicable psychological counselling

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: High Dose Vitamin C in Cardiac Surgery Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Scheduled for elective non-emergent valve repair or replacement, or multi-vessel CABG surgery~* No known coagulopathy prior to surgery~Exclusion Criteria:~* Emergency cardiac surgery~* Ejection fraction \< 35%~* Presence of autoimmune disease or currently receiving immunosuppressant therapy~* History of renal calculi~* Renal dysfunction (pre-operative creatinine clearance \< 40 mL/min, or serum creatinine greater than 1.8 mg/dl)~* Known bleeding diathesis~* Active infection, cancer or tumor~* Prior history of atrial fibrillation~* Single CABG procedure (one involved coronary vessel)~* Prisoner~* Pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Vitamin C (Type: EXPERIMENTAL): Intravenous ascorbic acid 50 mg/kg in 50 mL normal saline every six hours for 48 hours.
- Normal saline (Type: PLACEBO_COMPARATOR): Intravenous normal saline 50 mL every six hours for 48 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Health Economic Study Evaluating the Brain Sentinel® GTC Seizure Detection and Information Systems Impact on Epilepsy and Healthcare Utilization

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject has a history of GTC seizures, either primary GTC or partial onset seizures with secondary generalization~* Male or female greater than 2 years of age~* Has an upper arm circumference which is adequate for proper fit of the EMG monitor (at least 16-51 cm)~* Be able to tolerate wearing the device on the upper arm~* Can understand and sign written informed consent, or will have a parent or a legally authorized representative (LAR) who can do so, prior to the performance of any study assessments~* Subject and/or Primary Caregiver must be competent to follow all study procedures.~* Is able to read, speak and understand English~* At least 2 or more Emergency Department visits in the previous 12 months for seizure related care~Exclusion Criteria:~* The subject is homeless or in a home without a power supply.~* The subject is allergic to adhesives or any component of the electrode patch assembly.~* The subject self-reports that she is pregnant or planning to become pregnant while using the device.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues